Inbreeding abolishes the effect of parental origin of a mutant Rb-1 allele on pituitary tumorigenesis in mice.

The previously reported earlier onset of pituitary tumours in cross-bred mice inheriting a mutant Rb-1 allele paternally has been ascribed to imprinting of an Rb-1-linked gene. Here, we demonstrate that, as predicted from this mechanism, there is no effect of the parent of origin of the mutation in inbred mice.

Analysis of fused maxillary incisor dentition in p53-deficient exencephalic mice.

Out of a total of 21 exencephalic p53-deficient embryonic and newborn mice, 6 (28.6%) possessed fused maxillary incisor teeth. On histological analysis of the 5 examples seen on day 19.5 of gestation and newborn mice, 3 varieties were observed: an example of 'simple' fusion, 3 examples of simple fusion each of which contained a 'dens in dente' ('tooth within a tooth'), and a single example in which the fused teeth were associated with a median supernumerary incisor tooth which, while deeply indenting the labial surface of the fused teeth, was in all locations a completely separate unit. 3-D reconstructions of the fused teeth demonstrated that they were all of the fusio subtotalis variety. No gross abnormalities were observed in the other dentition in these mice. It is noted that in mice fused maxillary incisor teeth are relatively commonly associated with both hypervitaminosis A-induced and trypan blue-induced exencephaly. It is believed that the presence of dens in dente within fused maxillary incisor teeth has only once been reported in mice, and the association between fused maxillary incisor teeth and a median supernumerary incisor tooth has not previously been reported in this species.

High-frequency developmental abnormalities in p53-deficient mice.

BACKGROUND: Several strains of mice carrying null mutations of the tumour suppressor gene p53 have been developed. It has been reported that homozygous mice from all of these strains develop normally to birth, but then succumb rapidly to neoplasia. RESULTS: Here, we report that a significant proportion of female p53-/- mice die during embryogenesis or in the period between birth and weaning, being subject to a spectrum of abnormalities. In a significant proportion (23%) of p53-/- female embryos, the normal process of neural tube closure failed, leading to exencephaly and subsequent anencephaly. Although this phenomenon was predominantly associated with females, we observed one affected male embryo. In addition to a spectrum of neural tube defects, many of these embryos exhibited a range of craniofacial malformations, including ocular abnormalities and defects in upper incisor tooth formation. We observed a significant reduction in the number of p53-/- female progeny of p53+/- x p53+/- matings, and also in an in utero analysis of the p53+/- female progeny of p53-/- x p53+/+ matings. When male mice were exposed to irradiation prior to mating, a significant increase in the rate of abnormality was seen in the progeny, which was specifically associated with p53 deficiency. CONCLUSIONS: We have identified a high rate of developmental abnormalities associated with p53 deficiency. This manifests itself as a spectrum of lesions, predominantly female-associated defects in neural tube closure. These defects may arise either because p53 plays a physiological role at the time of neural tube closure, or because of an abnormally high frequency of mutation within the haploid gametes of p53-null parents.

Effects of heterozygosity for the Rb-1t19neo allele in the mouse.

We describe the pathology of a cohort of 80 mice heterozygous for an inactive allele of the Rb-1 tumour suppressor gene. The majority of these mice developed locally invasive tumours, arising from the pituitary gland. The time of onset of overt signs of disease in mice known to have inherited their mutant allele paternally shows a small but statistically significant shift to the lower end of the spectrum, suggesting that tumorigenesis is influenced by gametic imprinting. In situ hybridisation analysis demonstrates the presence in the tumours of pro-opiomelanocortin mRNA, which is normally found both in corticotroph and melanotroph cells. Mice within this cohort also develop systemic defects. Most notably, there is increased siderosis in the spleen indicating the possibility of an abnormality in red blood cell turnover. This is consistent with the abnormalities of erythropoiesis described previously in homozygous Rb-1-deficient mice. In addition, a proportion of mice developed liver steatosis, probably representing the end organ effects of hormonal imbalance as a direct consequence of tumour presence. A significant proportion showed C cell hyperplasia in the thyroid. The spectrum of pathology in mice differs from that in the human but does provide a useful model of site-specific tumour predisposition.

Embryonic kidney rudiments grown in adult mice fail to mimic the Wilms' phenotype, but show strain-specific morphogenesis.

12.5- to 14.5-day mouse embryonic kidney fragments were grown syngeneically under kidney or testis capsules in 3 mouse strains for 5-26 weeks to reproduce the Wilms' tumour (WT) phenotype previously reported. About 65% of the transplants grew, but none showed true WT morphology, invaded local tissue or developed metastases. In Swiss mice, most growths contained disorganized stromal and blast cells, but also had more mature structures. CBA growths had cysts, differentiated nephrons and glomeruli, while 129/SV growths gave both types of morphology. In situ mRNA hybridization using the Wilms' tumour predisposition gene (WT1) showed that, unlike the initial rudiments and WT, expression was limited to the glomeruli. The unexpected absence of expression by the apparent blast cells in the growths implies that the system is not a model for WT.

The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo.

In the developing mouse, the Wilms' tumour gene, WT1, is first expressed in the intermediate mesenchyme lateral to the coelomic cavity (13 somite, early 9 dpc embryo). A few hours later, it is present around all the cavity and in the urogenital ridge (the earliest mesonephric tubules) and the differentiating heart mesothelium. By 11 dpc, expression is in the uninduced metanephric mesenchyme and in the presumptive motor neurons of the spinal cord. By 12.5 dpc, WT1 expression has increased in the induced mesenchyme of the kidney and a day later is particularly marked in the nephrogenic condensations. At 13.5 dpc, WT1 is briefly expressed in some differentiating body-wall musculature, while two days later, there is a small domain of expression in the roof of the fourth ventricle of the brain. By day 20, however, expression has become restricted to the kidney glomeruli. RNA-PCR analysis on 12.5 dpc embryos and on adult tissues shows that WT1 is weakly expressed in both eye and tongue. The expression pattern in human embryos (28-70 days) is very similar to that in the equivalent mouse stages (10-15 dpc). The results indicate that WT1 is mainly present in mesodermally derived tissues, although exceptions are ectodermally derived spinal cord and brain. The data indicate that WT1 plays a role in mediating some cases of the mesenchyme-to-epithelial transition, but its expression elsewhere argues that it has other tissue-specific roles in development.